spacer
home > pmps > autumn 2008 > labelling: clarity and compliance
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Labelling: Clarity and Compliance

The legislation surrounding the clear and accurate labelling of pharmaceuticals, and the inclusion, where appropriate, of accompanying instruction leaflets, is becoming increasingly stringent. As a consequence, in addition to having to include mandatory information on medicinal products, pharmaceutical manufacturers and packaging companies are now required to ensure that this information is legible, easy to understand, and indelible. In order to achieve this using conventional printing technology, considerable time, money and resources can be required, leading these companies to look for a simpler and more cost-effective alternative.

Thankfully, a new generation of easy to operate and cost-effective printing equipment has been developed in response to these requirements, enabling the standards to be met with minimal expenditure and stress. Furthermore, these latest printers provide a sustainable solution, able to cater for evolving regulations and standards in order that they can continue to meet user requirements in the long term.

STRINGENT REGULATIONS

OEMs and packaging companies must now comply with the European Parliament Directive 2001/83/EC, which provides a number of guidelines concerning labelling pharmaceuticals and providing supporting documentation...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Mark Beauchamp is European Marketing Manager for Citizen Systems Europe. With over 18 years’ experience at the company and a wealth of technical knowledge, he is adept at helping channel partners and endusers alike to understand the latest printing technology. Beginning his career in the marketing team, Mark then moved into technical support where he provided distributor support across the European network. In addition to working with Citizen’s clients across Europe, the Middle East and Africa, he is actively involved in product development. Mark is Chairman of AIM UK, the British chapter of the Auto-ID manufacturers’ association.
spacer
Mark Beauchamp
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Validation batches of the vaccine against equine strangles Strangvac® is completed

[Noáin, January 27, 2020] 3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics has, together with the Swedish biotechnology company Intervacc AB and LIOF-Pharma (previously Praxis Pharmaceutical), completed the manufacturing process for the vaccine against equine strangles called Strangvac®. The validation production batches required for the forthcoming registration application to the European Medicines Agency, EMA, are thus finalized.
More info >>

White Papers

R&D to Product: How to Reduce Costly Scale-Up Problems

Natoli Engineering Company, Inc.

When scaling a new drug formulation from the development side of R&D into manufacturing, there is often a reality check with respect to process scaleup and performance of the formulation at production levels. Problems with capping/lamination and sticking/ picking are often first realized when a formulation is introduced to a level of compression required to supply market demand.
More info >>

 
Industry Events

World Vaccine Congress Washington

7-9 April 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement